A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.
The user is experiencing hair loss and has been using treatments like minoxidil, finasteride, and ciclopirox olamine. Despite these treatments, they are concerned about increased shedding, dandruff, and possible additional hair loss conditions.
The user has chronic itchy scalp and dandruff, unresponsive to ketoconazole, selenium sulfide, zinc pyrithione, coal tar, and salicylic acid. Topical steroids were also ineffective for long-term use.
A user is seeking a UK source for a combined minoxidil and RU58841 solution that doesn't contain scalp-irritating ingredients. They specifically want a product without propylene glycol (PG).
The conversation discusses using 0.1% Alfatradiol compounded by a pharmacy for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.
Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.
A user purchased an expensive hair loss treatment called Follicopeptide, which many others in the conversation believe to be a scam, suggesting instead the use of proven treatments like minoxidil and finasteride. Some users report positive effects from Follicopeptide, but skepticism remains high due to lack of transparency about its ingredients and the company's credibility.
Stemoxydine, a hair loss treatment, is reportedly discontinued, with some users suggesting alternatives like a rebranded version with resveratrol that may enhance Minoxidil. Some users express dissatisfaction with the discontinuation and question the product's value.
The conversation discusses a 4-month hair regrowth protocol that includes finasteride (1.25mg), RU58841, dermarolling, ketoconazole, minoxidil, peppermint oil, and fatty acids/oils. Progress pictures are shared to show the results of these treatments.
The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.
Pyrilutamide's effect on sebum production and scalp inflammation is unclear, with users noting no significant changes. Isotretinoin is mentioned as effective for reducing sebum, while Dutasteride and various shampoos have limited impact on oiliness and seborrheic dermatitis.
The conversation is about finding a source for Alfatradiol 0.1% as most available products are 0.025%. A suggestion was made to use four times the dosage of the 0.025% product.
A 31-year-old uses Minoxidil, RU58841, Reviv Hair Serum, and Ketoconazole shampoo for hair loss but avoids finasteride. They plan to reintroduce red light therapy (LLLT) and Eucapil despite previous shedding concerns.
User experienced scalp irritation from Kirkland 5% liquid minoxidil, likely due to propylene glycol. They are seeking non-PG liquid alternatives that are affordable.
A user noticing changes in the L'Oreal Serioxyl hair treatment, including a different smell, mismatched batch numbers, and a color change. They question if it's a new formula and seek alternatives to stemoxydine. Another user questions if the positive results were due to stemoxydine or other medications.
The conversation is about creating a DIY topical finasteride solution using ethyl alcohol and propylene glycol. A user suggests using a compounding pharmacy instead.
The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.
The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.
A user with diffuse thinning shares a tip for improving hair appearance by using a shea butter and coconut oil serum from Trader Joe's at night. They are on finasteride and considering adding minoxidil for better results.
A user with androgenic alopecia seeks advice on making topical spironolactone from pills due to poor reactions to the oral form and its unavailability in their country. They are looking for guidance on preparing it themselves.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
2-Deoxy-D-Ribose is discussed as a potential hair loss treatment, but skepticism exists due to lack of human testing. The original poster uses a combination of topical Minoxidil, oral Finasteride, topical RU58841, and other treatments, reporting some hair regrowth but not significant results.
The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.